Claude Science Debuts: AI Enters Drug Discovery, and the Checkpoint for Scientific Responsibility

At many research sites working on neglected diseases, the bottleneck is not necessarily only not knowing where to look for drugs. It also includes not having enough people to connect genomics, protein structures, compound databases, and high-performance computing. Anthropic’s newly launched Claude Science is aimed precisely at this long and tedious research workflow: letting AI not only answer questions, but also help execute analyses, call tools, and leave traceable research records.

NewsBytes described the news as Anthropic announcing an AI drug discovery program for neglected diseases. However, judging from Anthropic’s statements and product page, Claude Science itself is not a single drug development project designed only for neglected diseases, but a beta workbench for scientific research. Anthropic also announced that it will support up to 50 “AI for Science” Claude Science projects, with each project eligible for up to $30,000 in credits, and applications closing on July 15, 2026. This is where its connection to specific research topics, including possible disease research, is most direct.

This workbench comes preconfigured with skills and connectors needed in fields such as genomics, single-cell analysis, proteomics, structural biology, and cheminformatics. According to the product description, it can help researchers query scientific databases, run analytical workflows, manage computing resources from laptops to clusters and GPUs, and generate research outputs that are easier to audit. For drug discovery, this could cover protein structure prediction, molecular design, virtual screening, enzyme engineering, or large-scale single-cell data analysis.

Modal’s integration notes add a more concrete piece: researchers can connect Claude Science to their own Modal workspace, allowing workloads that require GPUs or large amounts of parallel CPU processing to be automatically sent to cloud sandboxes for execution. Modal also said it will provide up to $100,000 in compute resources for Anthropic’s AI for Science Claude Science cohort, with individual projects receiving about $500 to $2,000. This makes Claude Science not just a text interface, but more like a research environment that binds together conversation, code, databases, and scalable computing.

But the value of biomedical AI is not automatically established by an elegant workflow. If used for rare diseases or neglected diseases, the most realistic challenges are often scarce data, immature disease models, clinical endpoints that are hard to define, and even a lack of sufficient commercial incentives to push candidate molecules into expensive experiments and human trials. AI can accelerate hypothesis generation and candidate ranking, but it cannot replace wet-lab experiments, animal models, toxicology, process development, and regulatory review.

Another key issue is auditability. Anthropic emphasizes that Claude Science will generate traceable research outputs and support background checks for citations and computations. This is especially important for scientific research, because if AI merely outputs answers that look plausible, it may instead bring erroneous data, irreproducible analyses, or misunderstood literature into the R&D pipeline. What will truly enable researchers to adopt it is not how certain the AI sounds, but whether every step can be rerun, verified, and handed over for peer review.

Therefore, a more reasonable positioning for Claude Science is as a foundational tool that may lower the barrier to computational biology and early-stage drug discovery, rather than a guarantee of new drug discovery. Whether it can produce concrete results in neglected diseases will still depend on which diseases selected projects choose, which datasets they use, how they validate model outputs, and whether candidate molecules can move out of the computer and into a reliable chain of experimental evidence.